Edgar Filing: Amphastar Pharmaceuticals, Inc.

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Zhang Jack Y.

2. Issuer Name and Ticker or Trading Symbol
Amphastar Pharmaceuticals, Inc. [AMPH]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
CEO & Chief Science Officer

(Last)

(First)

(Middle)

C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2015

(Street)

RANCHO CUCAMONGA, CA 91730

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/05/2015		F		4,831 ⁽¹⁾	D	$ 16.4642	917,306	D
Common Stock	06/08/2015		F		3,046 ⁽¹⁾	D	$ 16.614	914,260	D
Common Stock	06/09/2015		F		2,624 ⁽¹⁾	D	$ 16.2356	911,636	D
Common Stock	06/10/2015		M		12,975	A	$ 12.97	924,611	D
Common Stock	06/10/2015		S⁽²⁾		11,731	D	$ 16.3792 ⁽³⁾	912,880	D
Common Stock	06/10/2015		F		1,244 ⁽⁴⁾	D	$ 16.3792	911,636	D
Common Stock	06/11/2015		M		12,860	A	$ 12.97	924,496	D
Common Stock	06/11/2015		S⁽²⁾		11,600	D	$ 16.4694 ⁽⁵⁾	912,896	D
Common Stock	06/11/2015		F		1,260 ⁽⁴⁾	D	$ 16.4694	911,636	D
Common Stock	06/12/2015		M		83,253	A	$ 12.97	994,889	D
Common Stock	06/12/2015		S⁽²⁾		75,618	D	$ 16.1487 ⁽⁶⁾	919,271	D
Common Stock	06/12/2015		F		7,635 ⁽⁴⁾	D	$ 16.1487	911,636	D
Common Stock	06/05/2015		F		6,173 ⁽¹⁾	D	$ 16.4657	667,351	I	See footnote ⁽⁷⁾
Common Stock	06/08/2015		F		3,052 ⁽¹⁾	D	$ 16.6087	664,299	I	See footnote ⁽⁷⁾
Common Stock	06/09/2015		F		2,633 ⁽¹⁾	D	$ 16.2339	661,666	I	See footnote ⁽⁷⁾
Common Stock	06/10/2015		M		12,619	A	$ 12.97	674,285	I	See footnote ⁽⁷⁾
Common Stock	06/10/2015		S⁽²⁾		11,411	D	$ 16.3719 ⁽⁸⁾	662,874	I	See footnote ⁽⁷⁾
Common Stock	06/10/2015		F		1,208 ⁽⁴⁾	D	$ 16.3719	661,666	I	See footnote ⁽⁷⁾
Common Stock	06/11/2015		M		12,930	A	$ 12.97	674,596	I	See footnote ⁽⁷⁾
Common Stock	06/11/2015		S⁽²⁾		11,664	D	$ 16.4689 ⁽⁹⁾	662,932	I	See footnote ⁽⁷⁾
Common Stock	06/11/2015		F		1,266 ⁽⁴⁾	D	$ 16.4689	661,666	I	See footnote ⁽⁷⁾
Common Stock	06/12/2015		M		42,223	A	$ 12.97	703,889	I	See footnote ⁽⁷⁾
Common Stock	06/12/2015		S⁽²⁾		38,471	D	$ 16.1673 ⁽¹⁰⁾	665,418	I	See footnote ⁽⁷⁾
Common Stock	06/12/2015		F		3,752 ⁽⁴⁾	D	$ 16.1673	661,666	I	See footnote ⁽⁷⁾
Common Stock								7,631,594	I	See footnote ⁽¹¹⁾
Common Stock								5,000	I	See footnote ⁽¹²⁾
Common Stock								200,000	I	See footnote ⁽¹³⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Employee Stock Option (right to buy)

$ 12.97

06/10/2015

12,975

⁽¹⁴⁾

09/28/2015

Common Stock

12,975

$ 0

154,655

Employee Stock Option (right to buy)

$ 12.97

06/11/2015

12,860

⁽¹⁴⁾

09/28/2015

Common Stock

12,860

$ 0

141,795

Employee Stock Option (right to buy)

$ 12.97

06/12/2015

83,253

⁽¹⁴⁾

09/28/2015

Common Stock

83,253

$ 0

58,542

Employee Stock Option (right to buy)

$ 12.97

06/10/2015

12,619

⁽¹⁴⁾

09/28/2015

Common Stock

12,619

$ 0

63,634

See footnote ⁽⁷⁾

Employee Stock Option (right to buy)

$ 12.97

06/11/2015

12,930

⁽¹⁴⁾

09/28/2015

Common Stock

12,930

$ 0

50,704

See footnote ⁽⁷⁾

Employee Stock Option (right to buy)

$ 12.97

06/12/2015

42,223

⁽¹⁴⁾

09/28/2015

Common Stock

42,223

$ 0

8,481

See footnote ⁽⁷⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Zhang Jack Y. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	X	CEO & Chief Science Officer
Luo Mary Z. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	X	COO, Chief Scientist, Chairman

Signatures

/s/ Ken Stupak, by power of attorney for Jack Y. Zhang		06/12/2015
^**Signature of Reporting Person		Date
/s/ Ken Stupak, by power of attorney for Mary Z. Luo		06/12/2015
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reported securities were withheld to satisfy the Reporting Person's tax liability in connection with a previously reported option exercise.
(2)	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the each of the reporting persons on December 16, 2014.
(3)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.25 to $16.61, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5), (6), (8), (9) and (10) to this Form 4.
(4)	The reported securities were withheld to satisfy the Reporting Person's tax liability in connection with the reported reported option exercise.
(5)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.38 to $16.62, inclusive.
(6)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.02 to $16.49, inclusive.
(7)	The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
(8)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.24 to $16.55, inclusive.
(9)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.37 to $16.61, inclusive.
(10)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.03 to $16.39, inclusive.
(11)	The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons are the sole owners.
(12)	The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
(13)	The shares are held of record by a trust for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
(14)	Shares subject to the option are fully vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.